| pubmed-article:9532321 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C1260880 | lld:lifeskim |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C0035457 | lld:lifeskim |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C0700580 | lld:lifeskim |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:9532321 | lifeskim:mentions | umls-concept:C0242896 | lld:lifeskim |
| pubmed-article:9532321 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9532321 | pubmed:dateCreated | 1998-5-21 | lld:pubmed |
| pubmed-article:9532321 | pubmed:abstractText | The effects of the new ipratropium bromide nasal spray on rhinorrhea associated with perennial allergic rhinitis were studied in 219 patients over eight weeks in a multicenter, randomized, double-blind trial. The purpose of the study was to determine whether the new spray reduces nasal hypersecretion in allergic patients without causing excessive dryness or other potential cholinergic side effects. The investigators compared two doses of the spray (42 or 84 mcg/nostril t.i.d.) to placebo. Two hundred and nineteen patients were admitted to the study; 176 completed it. Study design included one week of screening to confirm a diagnosis of perennial allergic rhinitis with clinically significant rhinorrhea, one week of single-blind treatment with a placebo consisting of the saline vehicle of the spray, an eight-week double-blind treatment-comparison period, and one week of follow-up without treatment. Both doses of ipratropium bromide nasal spray significantly reduced the hypersecretion associated with PAR, compared with placebo. The two doses of active drug were equally effective. Treatment differences were noticeable during the first week and remained relatively stable during the eight-week treatment period. There was no evidence of nasal rebound after discontinuation of treatment. The incidence of side effects was comparable to placebo. The spray was well-tolerated, and was not associated with any significant adverse events. | lld:pubmed |
| pubmed-article:9532321 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9532321 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9532321 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9532321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9532321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9532321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9532321 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9532321 | pubmed:issn | 1088-5412 | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:GrossmanJJ | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:FindlayS RSR | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:GeorgitisJ... | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:TinkelmanD... | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:WoodC CCC | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:KaiserH BHB | lld:pubmed |
| pubmed-article:9532321 | pubmed:author | pubmed-author:RatnerP HPH | lld:pubmed |
| pubmed-article:9532321 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9532321 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:9532321 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9532321 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9532321 | pubmed:pagination | 23-9 | lld:pubmed |
| pubmed-article:9532321 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:meshHeading | pubmed-meshheading:9532321-... | lld:pubmed |
| pubmed-article:9532321 | pubmed:articleTitle | The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis. | lld:pubmed |
| pubmed-article:9532321 | pubmed:affiliation | University of Minnesota, Minneapolis 55402, USA. | lld:pubmed |
| pubmed-article:9532321 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9532321 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9532321 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9532321 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9532321 | lld:pubmed |
